Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 23Triple Negative Breast Neoplasms 5Stomach Neoplasms 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasms 2Esophageal Neoplasms 2Adenocarcinoma 2Resectable HER2-positive Breast Cancer 1Patients With Advanced or Metastatic Solid Tumors 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1

Interventions

Mitomycin 15Gemcitabine 13dodecyl maltoside 5BCG Vaccine 5erdafitinib 4apaziquone 4ALT-803 4Epirubicin 3viscum album peptide 2durvalumab 2VB4-845 2Imiquimod 2Docetaxel 25-aminolevulinic acid hexyl ester 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1pirarubicin 1pembrolizumab 1linrodostat 1hydroxycamptothecinum 1enfortumab vedotin 1catumaxomab 1Water 1Therapeutics 1Therapeutic Uses 1Standard of Care 1Polysorbates 1Photochemotherapy 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Non-Muscle Invasive Bladder Neoplasms × Epirubicin × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04490993 2022-02-22

ACCRUE

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 3 Unknown
359 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04736394 2022-02-22

ASCERTAIN

Jiangsu Yahong Meditech Co., Ltd aka Asieris

Phase 3 Unknown
800 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡